Enrollment Begins in Oxigene Tumor Trial
Posted on: Thursday, 9 November 2006, 15:01 CST
Oxigene has started patient dosing in its phase Ib trial in advanced solid tumors which combines its lead vascular disrupting agent, CA4P, with antiangiogenic agent Avastin.
In recent published research, the combination of a Vascular Disrupting Agent (VDA) with an antiangiogenic agent was described as offering a powerful and highly targeted regimen for suppressing tumor growth.
"We believe that the combination of CA4P and Avastin has the potential to bring significant benefit to patients. This patient enrollment also highlights our renewed focus on executing our programs rapidly and on schedule," stated Dr Richard Chin, president and CEO of Oxigene.
Oxigene believes that this dose escalation trial is the first step toward fully elucidating the efficacy and safety profiles of combining VDAs and antiangiogenic agents in patients.
Oxigene is an emerging pharmaceutical company developing small-molecule therapeutics to treat cancer and eye diseases. The company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.
Source: Datamonitor
Related Articles
- OXiGENE Initiates Phase II Lung Cancer Study
- OXiGENE Begins Phase II NSCLC Trial of ZYBRESTAT(TM) in Combination With Bevacizumab and Chemotherapy
- OXiGENE Reports OXi4503 Phase I Interim Data; Mechanism-of-Action Data Published in Peer-Review Journal
- First Patient Enrolled in OXiGENE's Phase Ib Trial of Its Lead Vascular Disrupting Agent, CA4P, in Combination With an Antiangiogenic Agent, Bevacizumab (Avastin) for the Treatment of Advanced Cancer
- Oxigene Reports Positive Results From Cancer Trial
- OXiGENE to Focus Ophthalmology Strategy Toward Non-Invasive Administration of CA4P for Age-Related Macular Degeneration (AMD); Closes Enrollment of Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213)
- Oxigene's Ovarian Cancer Drug Gets Orphan Designation
- OXiGENE to Commence First Ever Oncology Clinical Trial Combining a Vascular Disrupting Compound, Combretastatin A4P, With an Anti-Angiogenic Agent, Avastin
- OXiGENE's Lead Drug Candidate CA4P Demonstrates Anti-Tumor Activity in Radiation Therapy-Based Treatments
 |
 |
User Comments (0)
RSS Feeds